Is TENX or LEXX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -61.54% -57.42% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts recommend NTRB or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 117.39%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TLPH or LEXX more profitable?

Talphera's return on equity of -87.28% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Lexaria Bioscience N/A -174.93% -143.89%

Which has better earnings & valuation, CLNN or LEXX?

Lexaria Bioscience has higher revenue and earnings than Clene. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 271.78 -$26.17M -$3.50 N/A Lexaria Bioscience $710K 24.05 -$11.90M -$5.10 N/A

Lexaria Bioscience (LEXX) Competitors

$10.35 -1.33 (-11.39%)

As of 08/28/2026 04:00 PM Eastern

Compare

LEXX vs. TENX, NTRB, TLPH, HRTX, and CLNN

Should you buy Lexaria Bioscience stock or one of its competitors? Lexaria Bioscience's main competitors and comparable companies include Tenax Therapeutics (TENX), Nutriband (NTRB), Talphera (TLPH), Heron Therapeutics (HRTX), and Clene (CLNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lexaria Bioscience compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Tenax Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Lexaria Bioscience has higher revenue and earnings than Tenax Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A

In the previous week, Tenax Therapeutics had 13 more articles in the media than Lexaria Bioscience. MarketBeat recorded 15 mentions for Tenax Therapeutics and 2 mentions for Lexaria Bioscience. Tenax Therapeutics' average media sentiment score of 1.50 beat Lexaria Bioscience's score of 0.96 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Positive
Lexaria Bioscience	Positive

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tenax Therapeutics' return on equity of -61.54% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Tenax Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 557.28%. Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 117.39%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenax Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tenax Therapeutics beats Lexaria Bioscience on 12 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Nutriband has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

19.7% of Nutriband shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lexaria Bioscience has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Nutriband has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	26.59	-$8.23M	-$2.58	N/A
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A

In the previous week, Lexaria Bioscience had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.96 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Lexaria Bioscience	Positive

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 117.39%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nutriband beats Lexaria Bioscience on 11 of the 16 factors compared between the two stocks.

How does Lexaria Bioscience compare to Talphera?

Talphera (NASDAQ:TLPH) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

37.7% of Talphera shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 150.00%. Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 117.39%. Given Talphera's stronger consensus rating and higher probable upside, research analysts clearly believe Talphera is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Talphera's return on equity of -87.28% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A

In the previous week, Lexaria Bioscience had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Talphera. Lexaria Bioscience's average media sentiment score of 0.96 beat Talphera's score of 0.65 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Positive
Lexaria Bioscience	Positive

Summary

Talphera beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Lexaria Bioscience has lower revenue, but higher earnings than Heron Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexaria Bioscience has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Lexaria Bioscience's return on equity of -174.93% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Lexaria Bioscience	N/A	-174.93%	-143.89%

In the previous week, Lexaria Bioscience had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Lexaria Bioscience's score of 0.96 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Very Positive
Lexaria Bioscience	Positive

Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 512.37%. Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 117.39%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Heron Therapeutics beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks.

How does Lexaria Bioscience compare to Clene?

Clene (NASDAQ:CLNN) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Lexaria Bioscience has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Clene presently has a consensus target price of $33.25, indicating a potential upside of 686.05%. Lexaria Bioscience has a consensus target price of $22.50, indicating a potential upside of 117.39%. Given Clene's stronger consensus rating and higher possible upside, equities analysts clearly believe Clene is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lexaria Bioscience had 1 more articles in the media than Clene. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Clene. Clene's average media sentiment score of 1.89 beat Lexaria Bioscience's score of 0.96 indicating that Clene is being referred to more favorably in the media.

Company	Overall Sentiment
Clene	Very Positive
Lexaria Bioscience	Positive

Clene has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Lexaria Bioscience has higher revenue and earnings than Clene. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	271.78	-$26.17M	-$3.50	N/A
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A

23.3% of Clene shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Clene beats Lexaria Bioscience on 12 of the 16 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.10M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-2.03	787.65	273.16	25.42
Price / Sales	24.05	755.84	630.81	94.42
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	5.18	10.49	11.08	6.36
Net Income	-$11.90M	$2.83B	$3.48B	$349.79M
7 Day Performance	-5.13%	0.39%	0.13%	-0.80%
1 Month Performance	74.11%	5.34%	7.08%	4.13%
1 Year Performance	-21.62%	6.05%	24.67%	15.17%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	2.5419 of 5 stars	$10.35 -11.4%	$22.50 +117.4%	-21.6%	$17.10M	$710K	N/A	7	Short Interest Decrease Gap Down
TENX Tenax Therapeutics	4.145 of 5 stars	$2.32 +25.4%	$14.00 +503.4%	-64.4%	$69.23M	N/A	N/A	9	Positive News Short Interest Increase
NTRB Nutriband	0.4249 of 5 stars	$4.83 -5.5%	N/A	-31.1%	$62.12M	$2.04M	N/A	10	Positive News
TLPH Talphera	2.7939 of 5 stars	$1.23 +3.4%	$3.00 +143.9%	+121.8%	$61.77M	$30K	N/A	19
HRTX Heron Therapeutics	2.4532 of 5 stars	$0.32 +0.1%	$2.00 +519.0%	-75.8%	$61.28M	$154.90M	N/A	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TENX, NTRB, TLPH, HRTX, and CLNN

How does Lexaria Bioscience compare to Tenax Therapeutics?

Summary

How does Lexaria Bioscience compare to Nutriband?

Summary

How does Lexaria Bioscience compare to Talphera?

Summary

How does Lexaria Bioscience compare to Heron Therapeutics?

Summary

How does Lexaria Bioscience compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TENX, NTRB, TLPH, HRTX, and CLNN

How does Lexaria Bioscience compare to Tenax Therapeutics?

Which has more risk and volatility, TENX or LEXX?

Which has preferable valuation & earnings, TENX or LEXX?

Does the media favor TENX or LEXX?

Do institutionals & insiders have more ownership in TENX or LEXX?

Is TENX or LEXX more profitable?

Do analysts recommend TENX or LEXX?

Summary

How does Lexaria Bioscience compare to Nutriband?

Which has more volatility and risk, NTRB or LEXX?

Do institutionals & insiders believe in NTRB or LEXX?

Is NTRB or LEXX more profitable?

Which has preferable valuation & earnings, NTRB or LEXX?

Does the media refer more to NTRB or LEXX?

Do analysts recommend NTRB or LEXX?

Summary

How does Lexaria Bioscience compare to Talphera?

Which has more volatility and risk, TLPH or LEXX?

Do insiders & institutionals have more ownership in TLPH or LEXX?

Do analysts recommend TLPH or LEXX?

Is TLPH or LEXX more profitable?

Which has higher valuation & earnings, TLPH or LEXX?

Does the media favor TLPH or LEXX?

Summary

How does Lexaria Bioscience compare to Heron Therapeutics?

Which has preferable valuation & earnings, HRTX or LEXX?

Do institutionals & insiders have more ownership in HRTX or LEXX?

Is HRTX or LEXX more profitable?

Does the media prefer HRTX or LEXX?

Which has more risk & volatility, HRTX or LEXX?

Do analysts rate HRTX or LEXX?

Summary

How does Lexaria Bioscience compare to Clene?

Is CLNN or LEXX more profitable?

Do analysts rate CLNN or LEXX?

Does the media favor CLNN or LEXX?

Which has more risk and volatility, CLNN or LEXX?

Which has better earnings & valuation, CLNN or LEXX?

Do institutionals and insiders hold more shares of CLNN or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools